Arcturus Therapeutics Holdings (ARCT) Non-Current Deffered Revenue (2018 - 2025)
Arcturus Therapeutics Holdings (ARCT) posted Non-Current Deffered Revenue of $4.2 million for Q3 2025, down 51.88% on a QoQ basis from $8.8 million in Q2 2025, and down 68.36% year-over-year from $13.3 million in Q3 2024.
Arcturus Therapeutics Holdings (ARCT) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
Arcturus Therapeutics Holdings' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $4.2 million for Q3 2025.
- Quarterly Non-Current Deffered Revenue fell 68.36% year-over-year to $4.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.2 million (down 68.36% YoY) and the FY2024 annual result came in at $12.6 million, down 70.34% from the prior year.
- Non-Current Deffered Revenue was $4.2 million for Q3 2025 at Arcturus Therapeutics Holdings, down from $8.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $42.5 million in Q4 2023 and bottomed at $4.2 million in Q3 2025.
- A 5-year average of $15.2 million and a median of $11.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue soared 709.25% — and 2024, when it plunged 70.34%.
- Arcturus Therapeutics Holdings' Non-Current Deffered Revenue stood at $19.9 million in 2021, then rose by 0.7% to $20.1 million in 2022, then jumped by 111.73% to $42.5 million in 2023, then plunged by 70.34% to $12.6 million in 2024, then sank by 66.52% to $4.2 million in 2025.
- Business Quant data shows ARCT's Non-Current Deffered Revenue at $4.2 million in Q3 2025, $8.8 million in Q2 2025, and $9.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4.22 Mn |
| Jun 30, 2025 | 8.77 Mn |
| Mar 31, 2025 | 9.63 Mn |
| Dec 31, 2024 | 12.60 Mn |
| Sep 30, 2024 | 13.34 Mn |
| Jun 30, 2024 | 11.34 Mn |
| Mar 31, 2024 | 11.80 Mn |
| Dec 31, 2023 | 42.50 Mn |
| Sep 30, 2023 | 41.91 Mn |
| Jun 30, 2023 | 25.73 Mn |
| Mar 31, 2023 | 20.57 Mn |
| Dec 31, 2022 | 20.07 Mn |
| Sep 30, 2022 | 5.18 Mn |
| Jun 30, 2022 | 5.59 Mn |
| Mar 31, 2022 | 6.64 Mn |
| Dec 31, 2021 | 19.93 Mn |
| Sep 30, 2021 | 8.50 Mn |
| Jun 30, 2021 | 9.85 Mn |
| Mar 31, 2021 | 11.31 Mn |
| Dec 31, 2020 | 12.51 Mn |